Cure My Disease

Don't miss your cure!

 Log in / Sign up

4-Year arthritis drug study shows promise for kids

NCT ID NCT03769168

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety and effectiveness of the drug secukinumab in children with two types of juvenile idiopathic arthritis: juvenile psoriatic arthritis and enthesitis related arthritis. Fifty-five children who had already completed a previous study continued treatment for up to 4 years. The goal was to see if the drug kept working and remained safe over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENTHESITIS RELATED ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

enthesitis-related juvenile idiopathic arthritis juvenile idiopathic arthritis psoriasis-related juvenile idiopathic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENTHESITIS RELATED ARTHRITIS JUVENILE PSORIATIC ARTHRITIS

Contacts and locations

Locations

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio, 45229, United States

  • Legacy Emanuel Research Hospital Portland

    Portland, Oregon, 97232, United States

  • Novartis Investigative Site

    Brussels, 1200, Belgium

  • Novartis Investigative Site

    Ghent, 9000, Belgium

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Hamburg, 22081, Germany

  • Novartis Investigative Site

    Saint Augustin, 53757, Germany

  • Novartis Investigative Site

    Genova, GE, 16147, Italy

  • Novartis Investigative Site

    Naples, 80131, Italy

  • Novartis Investigative Site

    Krakow, 31503, Poland

  • Novartis Investigative Site

    Moscow, 119991, Russia

  • Novartis Investigative Site

    Saint Petersburg, 194100, Russia

  • Novartis Investigative Site

    Voronezh, 394036, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620149, Russia

  • Novartis Investigative Site

    Panorama, Western Cape, 7500, South Africa

  • Novartis Investigative Site

    Cape Town, 7925, South Africa

  • Novartis Investigative Site

    Santiago de Compostela, Galicia, 15706, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Istanbul, Halkali, 34303, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, TUR, 34098, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06230, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, 34093, Turkey (Türkiye)

  • St Lukes Intermountain Research Center

    Boise, Idaho, 83702, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.